Skip to main content
. Author manuscript; available in PMC: 2011 Jan 20.
Published in final edited form as: Cancer Sci. 2008 Apr;99(4):696–705. doi: 10.1111/j.1349-7006.2008.00752.x

Fig. 3.

Fig. 3

The effect of a phosphatidyl choline specific phospholipase C (PC-PLC) inhibitor on 1-methylanthracene (1-MeA)-induced activation of extracellular receptor kinase (ERK) and p38. (a) The activation of ERK and p38 was determined by Western blot analysis using phosphospecific antibodies. (b) The densitometry analyzes of the three independent Western blot experiments including those shown in (a) of the mitogen activated protein kinase (MAPK) bands relative to the house keeping protein, GAPDH. (a,b) The dose and time of 1-MeA was 75 μM and 30 min. The PC-PLC inhibitor, 50 μM of D609, was added 20 min prior to 1-MeA and remained on the cells for an additional 30 min after the 1-MeA was added. The D609 control was 50 min. The first two lanes was the vehicle. Using a two-tailed t-test, the letter A in (b) indicates no significant difference in the p42 band between the 1-MeA and 1-MeA + D609 treatment (t = −0.548, P = 0.613). Similarly, the letter B indicated no difference in the p44 band (t = −0.000, P = 1.000) and the letter C indicated no difference in the p38 band (t = −0.0418, P = 0.969) between the 1-MeA and 1-MeA + D609 treatment.